Cargando…

Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria

BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive thoracic malignancy that is difficult to cure. Dynamic contrast-enhanced (DCE) MRI is a functional imaging technique used to analyze tumor microvascular properties and to monitor therapy response. Purpose of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vivoda Tomšič, Martina, Bisdas, Sotirios, Kovač, Viljem, Serša, Igor, Šurlan Popovič, Katarina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391827/ https://www.ncbi.nlm.nih.gov/pubmed/30813957 http://dx.doi.org/10.1186/s40644-019-0189-5

Ejemplares similares

Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy
por: Vivoda Tomšič, Martina, et al.
Publicado: (2022)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Blood-brain barrier permeability imaging using perfusion computed tomography
por: Avsenik, Jernej, et al.
Publicado: (2015)

RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Yu, Hongli, et al.
Publicado: (2022)

Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
por: Öcal, Osman, et al.
Publicado: (2022)

Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2017)

Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria
por: Kidd, Andrew C, et al.
Publicado: (2022)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma
por: Strbac, Danijela, et al.
Publicado: (2018)

Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients
por: Kovac, Viljem, et al.
Publicado: (2012)

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
por: Kuroda, Hidekatsu, et al.
Publicado: (2022)

The Influence of Genetic Variability in IL1B and MIR146A on the Risk of Pleural Plaques and Malignant Mesothelioma
por: Piber, Petra, et al.
Publicado: (2020)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

Investigating the value of radiomics stemming from DSC quantitative biomarkers in IDH mutation prediction in gliomas
por: Ioannidis, Georgios S., et al.
Publicado: (2023)

3T MRI in evaluation of asbestos-related thoracic diseases – preliminary results
por: Podobnik, Janez, et al.
Publicado: (2010)

Non-contrast computed tomography in the diagnosis of cerebral venous sinus thrombosis
por: Avsenik, Jernej, et al.
Publicado: (2016)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma
por: Goričar, Katja, et al.
Publicado: (2017)

Prognostic Role of Diffusion Weighted and Dynamic Contrast-enhanced MRI in Loco-regionally Advanced Head and Neck Cancer Treated with Concomitant Chemoradiotherapy
por: Garbajs, Manca, et al.
Publicado: (2019)

Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score
por: Grosso, Federica, et al.
Publicado: (2021)

Multicenter DSC–MRI-Based Radiomics Predict IDH Mutation in Gliomas
por: Manikis, Georgios C., et al.
Publicado: (2021)

Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2019)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

Dynamic Susceptibility Contrast Enhanced (DSC) MRI Perfusion and Plasma Cytokine Levels in Patients after Tonic-clonic Seizures
por: Filipovic, Tatjana, et al.
Publicado: (2017)

Clinical indications and acquisition protocol for the use of dynamic contrast-enhanced MRI in head and neck cancer squamous cell carcinoma: recommendations from an expert panel
por: Romeo, Valeria, et al.
Publicado: (2022)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
por: Ades, Felipe, et al.
Publicado: (2015)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

The Influence of Genetic Variability of DNA Repair Mechanisms on the Risk of Malignant Mesothelioma
por: Levpuscek, Kristina, et al.
Publicado: (2019)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma
por: Goričar, Katja, et al.
Publicado: (2015)

Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma
por: Kovac, Viljem, et al.
Publicado: (2015)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

The Influence of Genetic Variability on the Risk of Developing Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2018)

Serum Calretinin as a Biomarker in Malignant Mesothelioma
por: Zupanc, Cita, et al.
Publicado: (2021)

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
por: Kim, Hong Deok, et al.
Publicado: (2019)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9flcfb4tejrchjgoal2583500a